Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Endocrinology

Long-term Monitoring and Health Priorities

At a Glance

Long-term care for aromatase deficiency focuses on protecting bone health, checking metabolism, recognizing ovarian torsion as an emergency, and discussing fertility. Monitoring with bone-density scans, selected blood tests, and specialist follow-up is individualized.

Living with aromatase deficiency requires a shift from “seeking a diagnosis” to “maintaining health.” Because this condition affects the body’s primary architectural and metabolic systems, long-term care focuses on protecting your bones, managing your metabolism, and watching for rare but serious physical changes.

Protecting Your Skeleton

Bone health is perhaps the most critical part of long-term monitoring. Estrogen is essential for building and maintaining bone mass. Without it, bones can remain thin and growth plates can stay open much longer than they should [1][2].

  • DXA Scans: Doctors use Dual-Energy X-ray Absorptiometry (DXA) to measure bone mineral density. Your clinician will recommend an individualized schedule for DXA scans, as there is no single schedule for all ages [3][4]. Pediatric results should generally be reported with age- and size-adjusted Z-scores, and osteoporosis in children is not diagnosed from low bone density alone.
  • Bone Age X-rays: Until the epiphyses (growth plates) are fully fused, your doctor will likely use clinician-selected X-rays of the hand and wrist to track skeletal maturity [2][5].
  • The Puberty Window: Research shows that bone deficits can sometimes emerge during puberty even if measurements were normal in childhood, making this a high-priority time for monitoring [3].

Metabolic Health

Aromatase deficiency can influence how your body processes sugar and fat, though this varies significantly between individuals [6][4].

  • Routine Screenings: Your medical team should periodically check your blood pressure, weight, and body mass index (BMI).
  • Lab Monitoring: If metabolic surveillance is recommended by your clinician based on the limited condition-specific evidence, they may use fasting glucose and/or HbA1c to monitor insulin resistance, alongside lipid profiles to check cholesterol and triglycerides [4][2]. The frequency of these tests is individualized.

Emergency Signal: Ovarian Torsion

For 46,XX individuals, the most significant “red flag” involves the ovaries. About 43% of 46,XX patients in a review of reported cases developed ovarian cysts, which can grow quite large [2]. These cysts can cause the ovary to become heavy and unstable, leading to ovarian torsion.

This is a medical emergency. Torsion occurs when the ovary twists on its blood supply, which can lead to permanent damage if not treated immediately [7][8].

  • The Warning Signs: Sudden, severe lower-abdominal or pelvic pain, often accompanied by nausea and vomiting [8][9].
  • A Crucial Note: Sometimes the pain and nausea can go away for a short time and then return. A “lull” in symptoms does not mean the emergency has passed; you still need immediate medical evaluation [9].
  • ACTION STATEMENT: New, persistent, worsening, recurrent, or severe pelvic/abdominal pain—especially if accompanied by nausea, vomiting, fainting, fever, or marked tenderness—requires urgent medical assessment at an emergency department.

Looking Toward the Future: Fertility

Fertility is a complex topic in aromatase deficiency, and research is still evolving.

  • For 46,XX Patients: While many experience primary amenorrhea (no periods) without treatment, estrogen therapy along with cyclic progestogen commonly produces predictable withdrawal bleeding or uterine cycling [10][11]. This bleeding does not demonstrate normal ovarian function or ovulation, and reproductive potential remains uncertain [2][12].
  • For 46,XY Patients: Outcomes are variable. Some individuals have been found to have azoospermia (absence of sperm), while others have maintained sperm production while receiving carefully managed estrogen therapy [13][14].

Because every person’s genetic mutation is unique, fertility should be discussed with a reproductive specialist who can perform individualized assessments of ovarian or testicular function, and mention timely fertility-preservation discussions such as semen cryopreservation or consultation about ovarian options when clinically appropriate [12][14].

Common questions in this guide

How often should I have a DXA bone-density scan with aromatase deficiency?
There is no single DXA schedule for everyone with aromatase deficiency. Your clinician will individualize the timing based on factors such as age, growth, bone health, and treatment; in children, results are generally interpreted using age- and size-adjusted scores.
What do bone-age X-rays show in aromatase deficiency?
Until the growth plates are fully fused, hand and wrist X-rays can help clinicians track skeletal maturity. These images show how far bone development has progressed and help the care team plan future monitoring.
Which metabolic tests may be checked over time?
Long-term follow-up may include blood pressure, weight, body mass index, fasting glucose or HbA1c when clinically indicated, and a lipid profile for cholesterol and triglycerides. The tests and their frequency should be individualized by your clinician.
When does pelvic pain require emergency care with aromatase deficiency?
Sudden, severe, persistent, worsening, or returning lower-abdominal or pelvic pain—especially with nausea, vomiting, fainting, fever, or marked tenderness—needs immediate evaluation in an emergency department. In people with ovaries, this may signal ovarian torsion, in which the ovary twists and its blood supply can be damaged; symptoms that briefly improve can still be an emergency.
Can withdrawal bleeding after hormone therapy prove that I am ovulating?
For many 46,XX individuals, estrogen plus cyclic progestogen can produce predictable withdrawal bleeding or uterine cycling. This bleeding does not prove that the ovaries are working normally or that ovulation is occurring, so reproductive potential requires an individualized assessment.
How can fertility be assessed in aromatase deficiency?
A reproductive specialist can assess ovarian or testicular function with individualized testing. Depending on the findings and age, counseling may include timely fertility preservation, such as semen cryopreservation or discussion of ovarian options.
How might ovarian cysts be monitored in aromatase deficiency?
For 46,XX individuals, clinicians may discuss pelvic ultrasound and an individualized follow-up plan because ovarian cysts can become large. Ultrasound monitoring does not replace urgent assessment for sudden, severe, persistent, worsening, or recurrent pelvic or abdominal pain.

Get notified when new evidence is published on Aromatase deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (14)
  1. 1

    Aromatase enzyme deficiency in an adult male patient and the effects of estrogen replacement therapy: a rare cause of tall stature.

    Imre E, Akçay S, Yavuz DG

    Hormones (Athens, Greece) 2025; (24(2)):525-532 doi:10.1007/s42000-025-00640-8.

    PMID: 40048086
  2. 2

    Aromatase deficiency: A case series of 46, XX Chinese children and a systematic review of the literature.

    Fan L, Zhang B, Li L, Gong C

    Clinical endocrinology 2020; (93(6)):687-695 doi:10.1111/cen.14277.

    PMID: 32623730
  3. 3

    Accelerated Pubertal Tempo in a 46,XY Aromatase-Deficient Patient.

    Costanzo M, Garcia-Feyling J, Saraco N, et al.

    Hormone research in paediatrics 2018; (90(4)):275-282 doi:10.1159/000492128.

    PMID: 30173221
  4. 4

    Aromatase deficiency in a male patient - Case report and review of the literature.

    Miedlich SU, Karamooz N, Hammes SR

    Bone 2016; (93()):181-186 doi:10.1016/j.bone.2016.09.024.

    PMID: 27693882
  5. 5

    Bone Disease Associated with Inactivating Aromatase Mutations and its Management.

    Cavati G, Merlotti D, Cardamone P, et al.

    Calcified tissue international 2025; (116(1)):14 doi:10.1007/s00223-024-01330-0.

    PMID: 39751875
  6. 6

    Late Recognition of Aromatase Deficiency Following 16 Years of Misdiagnosis as Congenital Adrenal Hyperplasia: A Case with Coexisting Gonadoblastoma and Dysgerminoma.

    Alfadhli E, Turkistani A

    Journal of clinical research in pediatric endocrinology 2026; doi:10.4274/jcrpe.galenos.2026.2026-6-8.

    PMID: 42678028
  7. 7

    Novel CYP19A1 Mutations Extend the Genotype-Phenotype Correlation and Reveal the Impact on Ovarian Function.

    Praveen VP, Ladjouze A, Sauter KS, et al.

    Journal of the Endocrine Society 2020; (4(4)):bvaa030 doi:10.1210/jendso/bvaa030.

    PMID: 32318648
  8. 8

    Ischemic Gangrene Requiring Right Salpingo-Oophorectomy in a Patient With Ovarian Cyst Torsion and a History of Bilateral Ovarian Cysts: A Case Report.

    Doshi N, Kanani D, Garber L, et al.

    Cureus 2025; (17(5)):e83595 doi:10.7759/cureus.83595.

    PMID: 40476117
  9. 9

    Ultrasonographic whirlpool sign in ovarian torsion with dual mature teratomas: A case report and literature review.

    Varra FN, Fasoulopoulos A, Spathi E, et al.

    Medicine international 2026; (6(4)):38 doi:10.3892/mi.2026.322.

    PMID: 42200089
  10. 10

    [A novel CYP19A1 variant causing aromatase deficiency in a family: case report and literature review].

    Ren WQ, Sun XF, Xue Y, et al.

    Zhonghua nei ke za zhi 2026; (65(9)):999-1004 doi:10.3760/cma.j.cn112138-20260210-00086.

    PMID: 42733266
  11. 11

    An Intron 9 CYP19 Gene Variant (IVS9+5G>A), Present in an Aromatase-Deficient Girl, Affects Normal Splicing and Is Also Present in Normal Human Steroidogenic Tissues.

    Saraco N, Nesi-Franca S, Sainz R, et al.

    Hormone research in paediatrics 2015; (84(4)):275-82 doi:10.1159/000437142.

    PMID: 26279340
  12. 12

    Ovarian and uterine development and hormonal feedback mechanism in a 46 XX patient with CYP19A1 deficiency under low dose estrogen replacement.

    Burckhardt MA, Obmann V, Wolf R, et al.

    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2015; (31(5)):349-54 doi:10.3109/09513590.2014.995619.

    PMID: 25585547
  13. 13

    Aromatase deficiency in a tall man: Case report of two novel mutations and review of literature.

    Singhania P, Dash D, Dhar A, et al.

    Bone reports 2022; (17()):101642 doi:10.1016/j.bonr.2022.101642.

    PMID: 36504506
  14. 14

    Congenital aromatase deficiency in an adult male: A case report of clinical course and symptom reversal with estrogen supplementation.

    Coady P, Walia A, Hernandez B, et al.

    Urology case reports 2026; (66()):103417 doi:10.1016/j.eucr.2026.103417.

    PMID: 41908849

This page is for informational purposes only and does not constitute medical advice. Your endocrinology and reproductive-care teams should individualize monitoring, treatment, fertility counseling, and urgent evaluation for your situation.